Literature DB >> 12636984

In vitro activity of novel imidazole antifungal agent NND-502 against Malassezia species.

Katsuhisa Uchida1, Yayoi Nishiyama, Takashi Tanaka, Hideyo Yamaguchi.   

Abstract

The in vitro activity of NND-502, a novel antifungal imidazole compound, was tested against the three major Malassezia species by an agar dilution method with modified Dixon medium and compared with the activities of three reference antifungal drugs of topical use, lanoconazole (LCZ), bifonazole (BFZ) and terbinafine (TBF). The geometric mean (GM)-MICs of NND-502 for 25 strains of M. furfur, 15 strains of M. sympodialis and ten strains of M. slooffiae were approximately 1.4, 0.1 and 1.0 mg/l, respectively, showing the greatest activity against M. sympodialis and the least against M. slooffiae. These values were similar to that of LCZ, but four to 69 times lower than that of BFZ and two to three times lower than that of TBF. The results suggest that NND-502 might be beneficial in the treatment of Malassezia-associated skin diseases.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12636984     DOI： 10.1016/s0924-8579(02)00362-x

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


  6 in total

1.  In Vitro Activities of Luliconazole, Lanoconazole, and Efinaconazole Compared with Those of Five Antifungal Drugs against Melanized Fungi and Relatives.

Authors:  Gholam Reza Shokoohi; Hamid Badali; Hossein Mirhendi; Saham Ansari; Ali Rezaei-Matehkolaei; Bahram Ahmadi; Afsane Vaezi; Mohamed Mahdi Alshahni; Koichi Makimura
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

2.  Potent Activities of Luliconazole, Lanoconazole, and Eight Comparators against Molecularly Characterized Fusarium Species.

Authors:  Mahdi Abastabar; Abdullah M S Al-Hatmi; Mohammad Vafaei Moghaddam; G Sybren de Hoog; Iman Haghani; Seyed Reza Aghili; Tahereh Shokohi; Mohammad Taghi Hedayati; Roshanak Daie Ghazvini; Reza Kachuei; Ali Rezaei-Matehkolaei; Koichi Makimura; Jacques F Meis; Hamid Badali
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

3.  Antifungal Activity of a Novel Triazole, Efinaconazole and Nine Comparators against 354 Molecularly Identified Aspergillus Isolates.

Authors:  Zahra Taheri Rizi; Mahdi Abastabar; Hamed Fakhim; Macit Ilkit; Fatemeh Ahangarkani; Javad Javidnia; Iman Haghani; Jacques F Meis; Hamid Badali
Journal:  Mycopathologia       Date:  2020-02-28       Impact factor: 2.574

4.  Comparative assessment of the efficacy of topical ketoconazole and topical luliconazole in cases of pityriasis versicolor at a tertiary care hospital in eastern India: A prospective, open, randomized controlled trial.

Authors:  Somenath Sarkar; Dipayan Sengupta; Sukumar Basak; Shabab Ahmed Damji; Devesh Kumar Shukla; Deep Anurag
Journal:  Indian Dermatol Online J       Date:  2016 Jul-Aug

Review 5.  Treatment of superficial mycoses: review. Part II.

Authors:  Maria Fernanda Reis Gavazzoni Dias; Fred Bernardes-Filho; Maria Victória Pinto Quaresma-Santos; Adriana Gutstein da Fonseca Amorim; Regina Casz Schechtman; David Rubem Azulay
Journal:  An Bras Dermatol       Date:  2013 Nov-Dec       Impact factor: 1.896

Review 6.  Luliconazole for the treatment of fungal infections: an evidence-based review.

Authors:  Deepshikha Khanna; Subhash Bharti
Journal:  Core Evid       Date:  2014-09-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.